{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:25:35Z","timestamp":1786987535386,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.critrevonc.2024.104609","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T22:07:53Z","timestamp":1736028473000},"page":"104609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Efficacy and safety of PARP inhibitors in prostate cancer: An umbrella review of systematic reviews and meta-analyses"],"prefix":"10.1016","volume":"207","author":[{"given":"Chih-Chen","family":"Tzang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-An","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Tang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Fu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ming","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Ching","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bor-Show","family":"Tzang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2024.104609_bib1","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-024-03506-4","article-title":"Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","author":"Ai","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib2","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.3390\/curroncol30100669","article-title":"A meta-analysis of randomized clinical trials assessing the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer","volume":"30","author":"Alameddine","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2024.104609_bib4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.21037\/atm-21-1883","article-title":"Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials","volume":"9","author":"Bao","year":"2021","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.critrevonc.2024.104609_bib5","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1007\/s00018-011-0683-9","article-title":"ATM protein kinase: the linchpin of cellular defenses to stress","volume":"68","author":"Bhatti","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.critrevonc.2024.104609_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194904","article-title":"Hematological toxicities with PARp inhibitors in prostate cancer: a systematic review and meta-analysis of phase II\/III randomized controlled trials","volume":"15","author":"Bowling","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2024.104609_bib7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2024.104609_bib8","article-title":"Poly (ADP-ribose) Polymerase Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials","volume":"59","author":"Chao","year":"2023","journal-title":"Med. (Kaunas., Lith. )"},{"key":"10.1016\/j.critrevonc.2024.104609_bib9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/ijgc-2022-003990","article-title":"PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy","volume":"33","author":"Chelariu-Raicu","year":"2023","journal-title":"Int J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104609_bib10","article-title":"Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5489\/cuaj.1172","article-title":"Measuring quality of life after radical prostatectomy from the patient's perspective","volume":"3","author":"Chin","year":"2009","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.critrevonc.2024.104609_bib12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ccell.2019.05.001","article-title":"Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy","volume":"35","author":"Fang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2024.104609_bib13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3322\/caac.21720","article-title":"Genetic testing in prostate cancer management: Considerations informing primary care","volume":"72","author":"Giri","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2024.104609_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194771","article-title":"Molecular Characterization of Prostate Cancers in the Precision Medicine Era","volume":"13","author":"Giunta","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2024.104609_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102888","article-title":"Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis","volume":"147","author":"Gu","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib16","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41416-018-0274-8","article-title":"Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes","volume":"119","author":"Hodgson","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104609_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102623","article-title":"Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials","volume":"120","author":"Iannantuono","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2024.104609_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","article-title":"The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets","volume":"39","author":"Krishnakumar","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.critrevonc.2024.104609_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12885-021-09082-y","article-title":"Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets","volume":"22","author":"Lai","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2024.104609_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1290990","article-title":"Comparing efficacy of first-line treatment of metastatic castration resistant prostate cancer: a network meta-analysis of randomized controlled trials","volume":"14","author":"Liu","year":"2023","journal-title":"Front. PHARMACOLOGY"},{"key":"10.1016\/j.critrevonc.2024.104609_bib21","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","article-title":"The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer","volume":"215","author":"Li","year":"2018","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.critrevonc.2024.104609_bib22","article-title":"DNA Repair Pathways in Cancer Therapy and Resistance","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2024.104609_bib23","article-title":"BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib24","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/1120009X.2021.1884797","article-title":"Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II\/III randomized controlled trials","volume":"33","author":"Li","year":"2021","journal-title":"J. Chemother."},{"key":"10.1016\/j.critrevonc.2024.104609_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1265276","article-title":"Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Luo","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib26","first-page":"127","volume":"19","author":"Maiorano","year":"2023"},{"key":"10.1016\/j.critrevonc.2024.104609_bib27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ygyno.2021.05.012","article-title":"Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database","volume":"162","author":"Ma","year":"2021","journal-title":"GYNECOLOGIC Oncol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.euo.2023.07.013","article-title":"Combining PARP inhibitors and androgen receptor signalling inhibitors in metastatic prostate cancer: a quantitative synthesis and meta-analysis","volume":"7","author":"Messina","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib29","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-21-0098","article-title":"Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer","volume":"28","author":"Mitsiades","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104609_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41416-021-01295-z","article-title":"Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays","volume":"125","author":"Morice","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104609_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib32","first-page":"708","article-title":"Efficacy of PARP inhibitors as maintenance therapy for metastatic castration-resistant prostate cancer: a meta-analysis of randomized controlled trials","volume":"35","author":"Niazi","year":"2021","journal-title":"Oncol. (Williston Park"},{"key":"10.1016\/j.critrevonc.2024.104609_bib33","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00280-013-2113-1","article-title":"A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation","volume":"71","author":"Plummer","year":"2013","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.critrevonc.2024.104609_bib34","author":"Pollock","year":"2024","journal-title":"Chapter V: Overv. Rev."},{"key":"10.1016\/j.critrevonc.2024.104609_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104609_bib37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2019.06.012","article-title":"Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials","volume":"141","author":"Ruiz-Schutz","year":"2019","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib38","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104609_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib40","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/bju.16130","article-title":"Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis","volume":"132","author":"Sayyid","year":"2023","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2024.104609_bib41","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.critrevonc.2024.104609_bib42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejca.2021.02.035","article-title":"Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis","volume":"149","author":"Schettini","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104609_bib43","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1541-7786.MCR-13-0672","article-title":"Transcriptional roles of PARP1 in cancer","volume":"12","author":"Schiewer","year":"2014","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104609_bib44","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"Bmj"},{"key":"10.1016\/j.critrevonc.2024.104609_bib45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/jcpt.13300","article-title":"Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II\/III randomized controlled trials","volume":"46","author":"Sun","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.critrevonc.2024.104609_bib46","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104609_bib47","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/jcpt.13349","article-title":"Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials","volume":"46","author":"Wang","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.critrevonc.2024.104609_bib48","doi-asserted-by":"crossref","first-page":"518","DOI":"10.14740\/wjon1685","article-title":"Addition of olaparib to the new hormonal agent regimen for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"14","author":"Warli","year":"2023","journal-title":"World J. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib49","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fonc.2013.00290","article-title":"Beyond DNA Repair: Additional Functions of PARP-1 in Cancer","volume":"3","author":"Weaver","year":"2013","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.777663","article-title":"Evaluation of the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Wu","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.critrevonc.2024.104609_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104376","article-title":"Thromboembolic risk in prostate cancer patients treated with PARP inhibitors: A systematic review and meta-analysis","volume":"198","author":"Yazgan","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.critrevonc.2024.104609_bib52","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/ijc.32143","article-title":"Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas","volume":"145","author":"Yi","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104609_bib53","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1186\/s12885-024-12388-2","article-title":"The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis","volume":"24","author":"Zhu","year":"2024","journal-title":"BMC Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824003524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824003524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:22:31Z","timestamp":1740126151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824003524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":53,"alternative-id":["S1040842824003524"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104609","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of PARP inhibitors in prostate cancer: An umbrella review of systematic reviews and meta-analyses","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104609"}}